January 06, 2014
1 min read

Kala submits investigational new drug application

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Kala Pharmaceuticals has submitted an investigational new drug application to the U.S. Food and Drug Administration for a mucus-penetrating particle formulated loteprednol etabonate ophthalmic nano-suspension drug to treat inflammation and pain after cataract surgery, according to a press release.

The company’s mucus-penetrating particle technology platform allows therapeutic agents to pass through the mucus layer of the ocular surface, resulting in penetration into deeper eye tissues, including the aqueous humor and retina, according to the release.

Kala intends to initiate a phase 3 clinical trial to demonstrate anti-inflammatory efficacy similar to that of other steroid-based treatments with less frequent dosing while maintaining the safety profile of other loteprednol etabonate products, the release said.